Latest Posts:

Sorry, no posts matched your criteria.

Follow Us:

Back To Top

JOIN OUR EFFORTS TO

Overcome challenges in Cell and Gene Therapies

BY LAUNCHING NEW ADVANCED THERAPY VENTURES IN PARTNERSHIP WITH
ABOUT DSV

Deep Science Ventures is creating a future in which both humans and the planet can thrive.

We use our unique venture creation process to create, spin-out and invest into science companies, combining available scientific knowledge and founder-type scientists into high-impact ventures.

We operate in 4 sectors: Pharmaceuticals, Energy, Agriculture and Computation, tackling the challenges defining those areas by taking a first principles approach and partnering with leading institutions.

 

The Challenge

With the recent advances in cell and gene therapies it feels like cures to some of mankind’s most devastating diseases are within reach. We have seen CAR-T therapies cure some leukemias and the first approvals of gene therapies reversing rare diseases. This promise of being able to cure combined with technological advances have stimulated a lot of investment in the advanced therapies space. However, major hurdles still need to be overcome for cell and gene therapies to deliver on that promise and become mainstays of medicine rather than being reserved for rare diseases.

In order to be able to tackle the major markets, we need to find better ways for these therapies to reach their target tissues, we need to be able to reapply them if needed, we need them to stay clear of the liver and all of this needs to be done more cost effectively. Imagine the impact you’d have, if you could come up with a novel approach that overcomes immunogenicity; an approach that can deliver anywhere you want without ending up in the liver. Imagine finding ways that these treatments could be manufactured cheaply and efficiently? This would create patient impact across a variety of diseases with high unmet need.

 

Our take on building new ventures in this space

We are teaming up with with the CGT Catapult, an independent innovation and technology organisation with the aim to create powerful approaches that unlock the therapeutic potential of a wide range of research science and enable new therapeutic approaches in multiple medical conditions with high unmet need. You will be applying DSV’s approach to ideation whilst be able to tap into CGT Catapult’s network and expertise including technical, non-clinical and regs throughout the process.

 

Join us to build these ventures

You’ll join DSV as a Founding Analyst (fixed contract, full-time) and work with us for 9-12 months to further refine the approaches. At the end of the 9-12 month period you will have helped to design and spin-out one or more ventures, and will become a full-time Founder of one of them.

Taking up a Founding Analyst (FA) role at DSV differs quite significantly from the entrepreneur in residence (EIR) role in other funds or venture studios. Instead of scouting for existing technologies which might overcome a specific challenge, an FA starts with identifying the areas where there is neglect or repeated failure yet potential solutions exist if considered from a different perspective, mapping the limitations to existing approaches at the specific and macro-level and considering the constraints of the broader ecosystem (capital, expertise, IP, knowledge, competition). You will start to build a company, iteratively determining the optimal solution for the problem.

 

Our offer

We provide a monthly salary (at a pre-seed stage startup level) to bridge the gap between developing the concept and getting it to an investable company stage. You and your Co-Founder(s) will own 80% of the new venture at inception and the pre-seed investment capital is already secured from DSV. CGT Catapult will bring deep expertise in the space, apply time from their own staff to assist with the venture development process and – subject to investment committee decision – invest in kind in the new venture(s) through providing lab facilities at CGT Catapult.

 

Our impact

We’ve so far built from scratch and invested in 9 brand new companies in the curative therapeutics space, including the three oncology ventures we built last year in partnership with Cancer Research UK – read our Founder stories here.

 

Who should apply

We’re after a broad technical expertise across immunology, gene delivery, biomedical engineering, synthetic biology, stem cell, cell engineering, gene therapy and cell therapy, with a PhD in any of the aforementioned areas.

Needless to say that a strong desire to build a company to make a huge positive impact towards curative therapeutics is a must, you cannot wait to get started!

ABOUT DSV

Deep Science Ventures is creating a future in which both humans and the planet can thrive.

We use our unique venture creation process to create, spin-out and invest into science companies, combining available scientific knowledge and founder-type scientists into high-impact ventures.

We operate in 4 sectors: Pharmaceuticals, Energy, Agriculture and Computation, tackling the challenges defining those areas by taking a first principles approach and partnering with leading institutions.

 

The Challenge

With the recent advances in cell and gene therapies it feels like cures to some of mankind’s most devastating diseases are within reach. We have seen CAR-T therapies cure some leukemias and the first approvals of gene therapies reversing rare diseases. This promise of being able to cure combined with technological advances have stimulated a lot of investment in the advanced therapies space. However, major hurdles still need to be overcome for cell and gene therapies to deliver on that promise and become mainstays of medicine rather than being reserved for rare diseases.

In order to be able to tackle the major markets, we need to find better ways for these therapies to reach their target tissues, we need to be able to reapply them if needed, we need them to stay clear of the liver and all of this needs to be done more cost effectively. Imagine the impact you’d have, if you could come up with a novel approach that overcomes immunogenicity; an approach that can deliver anywhere you want without ending up in the liver. Imagine finding ways that these treatments could be manufactured cheaply and efficiently? This would create patient impact across a variety of diseases with high unmet need.

 

Our take on building new ventures in this space

We are teaming up with with the CGT Catapult, an independent innovation and technology organisation with the aim to create powerful approaches that unlock the therapeutic potential of a wide range of research science and enable new therapeutic approaches in multiple medical conditions with high unmet need. You will be applying DSV’s approach to ideation whilst be able to tap into CGT Catapult’s network and expertise including technical, non-clinical and regs throughout the process.

 

Join us to build these ventures

You’ll join DSV as a Founding Analyst (fixed contract, full-time) and work with us for 9-12 months to further refine the approaches. At the end of the 9-12 month period you will have helped to design and spin-out one or more ventures, and will become a full-time Founder of one of them.

Taking up a Founding Analyst (FA) role at DSV differs quite significantly from the entrepreneur in residence (EIR) role in other funds or venture studios. Instead of scouting for existing technologies which might overcome a specific challenge, an FA starts with identifying the areas where there is neglect or repeated failure yet potential solutions exist if considered from a different perspective, mapping the limitations to existing approaches at the specific and macro-level and considering the constraints of the broader ecosystem (capital, expertise, IP, knowledge, competition). You will start to build a company, iteratively determining the optimal solution for the problem.

 

Our offer

We provide a monthly salary (at a pre-seed stage startup level) to bridge the gap between developing the concept and getting it to an investable company stage. You and your Co-Founder(s) will own 80% of the new venture at inception and the pre-seed investment capital is already secured from DSV. CGT Catapult will bring deep expertise in the space, apply time from their own staff to assist with the venture development process and – subject to investment committee decision – invest in kind in the new venture(s) through providing lab facilities at CGT Catapult.

 

Our impact

We’ve so far built from scratch and invested in 9 brand new companies in the curative therapeutics space, including the three oncology ventures we built last year in partnership with Cancer Research UK – read our Founder stories here.

 

Who should apply

We’re after a broad technical expertise across immunology, gene delivery, biomedical engineering, synthetic biology, stem cell, cell engineering, gene therapy and cell therapy, with a PhD in any of the aforementioned areas.

Needless to say that a strong desire to build a company to make a huge positive impact towards curative therapeutics is a must, you cannot wait to get started!

Interviews will commence mid-Jan 2022

Interviews will commence mid-Jan 2022